200,000 Shares in MoonLake Immunotherapeutics $MLTX Acquired by Vestal Point Capital LP

Key Points

• Vestal Point Capital LP has acquired 200,000 shares of MoonLake Immunotherapeutics, valued at approximately $7.81 million, reflecting a 0.31% ownership in the company.
• Recent analyst reports have given MoonLake Immunotherapeutics an average rating of "Moderate Buy" with a consensus target price of $74.43 per share.
• MoonLake reported earnings of ($0.87) per share, missing the consensus estimate by $0.14, with expectations of posting (-$1.79) EPS for the current year.

Vestal Point Capital LP acquired a new position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm acquired 200,000 shares of the company's stock, valued at approximately $7,814,000. Vestal Point Capital LP owned 0.31% of MoonLake Immunotherapeutics as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in MoonLake Immunotherapeutics by 17.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 42,236 shares of the company's stock worth $2,287,000 after buying an additional 6,422 shares during the period. Victory Capital Management Inc. increased its holdings in shares of MoonLake Immunotherapeutics by 44.6% in the 1st quarter. Victory Capital Management Inc. now owns 258,150 shares of the company's stock valued at $10,086,000 after acquiring an additional 79,649 shares during the period. New York State Common Retirement Fund bought a new position in shares of MoonLake Immunotherapeutics in the 1st quarter worth $273,000. Rice Hall James & Associates LLC lifted its stake in shares of MoonLake Immunotherapeutics by 23.7% during the 1st quarter. Rice Hall James & Associates LLC now owns 137,516 shares of the company's stock worth $5,373,000 after purchasing an additional 26,383 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in MoonLake Immunotherapeutics during the fourth quarter valued at about $3,485,000. 93.85% of the stock is owned by institutional investors.

MoonLake Immunotherapeutics Stock Performance

Shares of NASDAQ:MLTX traded down $0.28 during midday trading on Friday, reaching $59.44. The company's stock had a trading volume of 1,519,917 shares, compared to its average volume of 432,083. The company has a quick ratio of 16.65, a current ratio of 16.65 and a debt-to-equity ratio of 0.21. The stock has a fifty day moving average of $52.89 and a 200 day moving average of $44.63. MoonLake Immunotherapeutics has a twelve month low of $31.42 and a twelve month high of $61.87. The firm has a market capitalization of $3.82 billion, a PE ratio of -21.38 and a beta of 1.27.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.73) by ($0.14). During the same quarter in the prior year, the firm posted ($0.39) earnings per share. On average, equities analysts expect that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Wall Street Analyst Weigh In

MLTX has been the topic of a number of recent analyst reports. The Goldman Sachs Group upped their price target on MoonLake Immunotherapeutics from $74.00 to $82.00 and gave the stock a "buy" rating in a research report on Wednesday, August 6th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $67.00 target price on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target for the company in a report on Monday, May 19th. Redburn Atlantic upgraded shares of MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Finally, Wedbush reaffirmed an "outperform" rating and issued a $80.00 price objective (up from $78.00) on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $74.43.

MoonLake Immunotherapeutics Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.